The University of Southampton
University of Southampton Institutional Repository

Does a Bevacizumab-based regime have a role in the treatment of children with diffuse intrinsic pontine glioma?: a systematic review

Does a Bevacizumab-based regime have a role in the treatment of children with diffuse intrinsic pontine glioma?: a systematic review
Does a Bevacizumab-based regime have a role in the treatment of children with diffuse intrinsic pontine glioma?: a systematic review

Background: There are no effective treatments for diffuse intrinsic pontine glioma (DIPG); median survival is 11.2 months. Bevacizumab has the potential to improve quality of life (QOL) and survival in DIPG but has never been evaluated systematically. The aim of this review was to assess Bevacizumab's role in the treatment of DIPG.

Methods: MEDLINE, EMBASE, Scopus, and Web of Science were searched for relevant studies using terms developed from alternatives for Bevacizumab and DIPG. One reviewer screened titles and abstracts, then two reviewers screened full texts. Data were extracted into tables and quality assessed using methodological index for non-randomized studies and JBI tools.

Results: Searching revealed 1001 papers; after deduplication 851 remained. After screening of titles and abstracts, then 28 full texts, 11 studies were included. Four studies reported a median overall survival longer than historical data, however, two found no significant impact of Bevacizumab. Five studies reported a radiological response in a proportion of participants and two reported no response. Three studies, evaluating clinical response, reported improvement in a proportion of patients. Three studies, evaluating QOL, reported stability or improvement. Four studies, evaluating steroid use, reported reductions in the proportion of patients receiving steroids. In radiation necrosis treatment, Bevacizumab led to clinical improvement in 6/12 patients in 2 studies and permitted a reduction in steroid use in most patients.

Conclusions: Insufficient evidence means the role of Bevacizumab in the treatment of DIPG is unclear. However, Bevacizumab may be beneficial to some patients. The review highlights the need for further research in this area.

2632-2498
Evans, Mia
966ad338-cec2-4ba2-9737-8ece43bdbf06
Gill, Ria
e586730f-d95c-48a0-bef7-dabd069be021
Bull, Kim S.
751f8b25-29ba-4d4f-96e2-6c339a83a47f
Evans, Mia
966ad338-cec2-4ba2-9737-8ece43bdbf06
Gill, Ria
e586730f-d95c-48a0-bef7-dabd069be021
Bull, Kim S.
751f8b25-29ba-4d4f-96e2-6c339a83a47f

Evans, Mia, Gill, Ria and Bull, Kim S. (2022) Does a Bevacizumab-based regime have a role in the treatment of children with diffuse intrinsic pontine glioma?: a systematic review. Neuro-Oncology Advances, 4 (1). (doi:10.1093/noajnl/vdac100).

Record type: Article

Abstract

Background: There are no effective treatments for diffuse intrinsic pontine glioma (DIPG); median survival is 11.2 months. Bevacizumab has the potential to improve quality of life (QOL) and survival in DIPG but has never been evaluated systematically. The aim of this review was to assess Bevacizumab's role in the treatment of DIPG.

Methods: MEDLINE, EMBASE, Scopus, and Web of Science were searched for relevant studies using terms developed from alternatives for Bevacizumab and DIPG. One reviewer screened titles and abstracts, then two reviewers screened full texts. Data were extracted into tables and quality assessed using methodological index for non-randomized studies and JBI tools.

Results: Searching revealed 1001 papers; after deduplication 851 remained. After screening of titles and abstracts, then 28 full texts, 11 studies were included. Four studies reported a median overall survival longer than historical data, however, two found no significant impact of Bevacizumab. Five studies reported a radiological response in a proportion of participants and two reported no response. Three studies, evaluating clinical response, reported improvement in a proportion of patients. Three studies, evaluating QOL, reported stability or improvement. Four studies, evaluating steroid use, reported reductions in the proportion of patients receiving steroids. In radiation necrosis treatment, Bevacizumab led to clinical improvement in 6/12 patients in 2 studies and permitted a reduction in steroid use in most patients.

Conclusions: Insufficient evidence means the role of Bevacizumab in the treatment of DIPG is unclear. However, Bevacizumab may be beneficial to some patients. The review highlights the need for further research in this area.

Text
vdac100 - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

e-pub ahead of print date: 24 June 2022
Published date: 14 July 2022
Additional Information: © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Identifiers

Local EPrints ID: 467674
URI: http://eprints.soton.ac.uk/id/eprint/467674
ISSN: 2632-2498
PURE UUID: 7b105359-8d76-4d0b-ab46-7ab72233c3bf
ORCID for Kim S. Bull: ORCID iD orcid.org/0000-0002-5541-4556

Catalogue record

Date deposited: 19 Jul 2022 16:36
Last modified: 20 Jul 2022 01:38

Export record

Altmetrics

Contributors

Author: Mia Evans
Author: Ria Gill
Author: Kim S. Bull ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×